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O B J E C T I V E S The goal of this study was to explore whether ﬁbrosis detected by late gadolinium
enhancement cardiac magnetic resonance (LGE-CMR) is an independent predictor of hard cardiovascular
events in patients presenting with ventricular arrhythmia.
B A C KG ROUND In patients at risk of sudden cardiac death, risk stratiﬁcation for device therapy
remains challenging.
METHOD S A total of 373 consecutive patients with sustained ventricular tachycardia (VT) (n  204)
or nonsustained ventricular tachycardia (NSVT) (n  169) underwent LGE-CMR. The group was
prospectively followed up for a median of 2.6 years (range 11 months to 11 years). The predetermined
endpoint was a composite of cardiac death/arrest, new episode of sustained VT, or appropriate
implantable cardioverter-deﬁbrillator discharge.
R E S U L T S Mean left ventricular (LV) ejection fraction (EF) was 60 13%. The presence of ﬁbrosis was
a strong and independent predictor of the primary outcome for the whole group (hazard ratio [HR]: 3.3,
95% conﬁdence interval [CI]: 1.8 to 5.8, p  0.001). In the sustained VT subset, both LV ﬁbrosis and
severely impaired systolic function (LVEF 35%) were signiﬁcant independent predictors in the
multivariate model (HR: 3.0, 95% CI: 1.4 to 6.2, p  0.001; and HR: 2.5, 95% CI: 1.1 to 6.2, p  0.038,
respectively). In the NSVT subset, the presence of ﬁbrosis was the only independent predictor of the
endpoint (HR: 4.2, 95% CI: 1.7 to 10.1, p  0.006).
CONC L U S I O N S LGE-CMR–detected ﬁbrosis is an independent predictor of adverse outcomes in
patients with ventricular arrhythmia and may have an important role in risk stratiﬁcation. (The
Prognostic Signiﬁcance of Fibrosis Detection in Ischemic and Non-Ischemic Cardiomyopathy;
NCT00930735) (J Am Coll Cardiol Img 2013;6:335–44) © 2013 by the American College of Cardiology
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336n patients presenting with ventricular arrhythmia,
accurate determination of the etiology and risk
stratification remains challenging. These patients
may be at risk of further ventricular arrhythmic
events, and some have an increased risk of sudden
cardiac death (SCD). Although device therapy has
a major protective benefit, patient selection remains
difficult.
See page 345
Current guidelines recommend device therapy in
preference to antiarrhythmic medication
in patients who are survivors of cardiac
arrest or sustained ventricular tachycardia
(VT) (secondary prevention), or in those
with significantly reduced left ventricular
(LV) ejection fraction (EF) (primary pre-
vention) (1). The majority of randomized
controlled studies that explored either
the secondary (2–4) or primary (5) pre-
vention benefit of automated implantable
cardioverter-defibrillator (AICD) either
enrolled only patients with reduced LVEF
or showed a predominant benefit in those
with reduced EF (6). Consequently, the
device therapy guidelines target predomi-
nantly those with reduced EF. However,
subsequent post hoc data analysis from the
AVID (Antiarrhythmics Versus Implant-
able Defibrillators) randomized controlled
trial (4) showed that patients with a clearly
defined lower risk profile are not likely to
benefit from secondary prevention AICD
(7). Coupled with reports from the
MADIT-II (Multicenter Automatic Defi-
brillator Implantation Trial II) cohort that a
significant proportion of patients implanted
for primary prevention never use their device
(5), the fact that defibrillator therapy re-
mains very expensive, has certain restrictive
lifestyle implications, and carries risks of
complications, it would be beneficial if refinements of
the current criteria could be added, on the basis of
stronger indices of prediction for those patients who
are at risk of further life-threatening ventricular ar-
rhythmias.
A well-established mechanism for arrhythmia is
the presence of myocardial fibrosis that predisposes
to re-entrant circuits (8,9). Late gadolinium en-
hancement (LGE) cardiac magnetic resonance
(CMR) is able to detect in vivo replacement fibrosis
ng
ble
se
ar
lar(10,11). CMR has emerged as an important pre- adictor of cardiovascular mortality and morbidity in
patients with both ischemic (12–14) and nonisch-
emic cardiomyopathy (14 –21). Several studies
showed that the presence, amount of scar, and scar
heterogeneity all appear to be important for both
inducible and spontaneous ventricular tachycardia
(VT) (22–26).
However, if myocardial fibrosis is to be a strong
predictor of malignant ventricular arrhythmia and
not a simple bystander at the end stage of disease
processes, its predictive value should extend to all
patients with myocardial fibrosis, independent of
their LVEF, whereas the absence of fibrosis should
indicate a population with a better outcome.
We sought to test this hypothesis by analyzing the
prognostic value of myocardial fibrosis in a consecutive
cohort of all-comers with documented ventricular
arrhythmias, with a known or suspected structural
cause for arrhythmia, who were referred for CMR.
M E T H O D S
Study patients. Consecutive patients with a recent
diagnosis of nonsustained VT (NSVT) or sustained
VT referred for CMR to the Royal Brompton
Hospital between 1999 and 2009 were prospectively
enrolled for follow-up of cardiac events. Reasons for
referral were further diagnostic evaluation: assess-
ment of cardiac structure and function, known or
suspected cardiomyopathy or nonacute ischemic
heart disease, assessment of anomalous coronary
origin, or valvular heart disease. Cases of congenital
VT (catecholaminergic, Brugada, or idiopathic QT
syndromes, diagnosed on the basis of the family
history, electrocardiogram [ECG], and where avail-
able, genetic testing for known genes at the time of
referral) were not included in this analysis. The
study was approved by the institutional ethics com-
mittee, and the subjects gave full informed consent.
Cardiac magnetic resonance. A 1.5-T Siemens scan-
er (Siemens, Munich, Germany) was used. After
ocalizer scans, cine images were acquired in 3 long
xes, followed by a full short-axis cine stack in all
atients and a LGE study. Gadolinium DTPA
Gadovist, Bayer, Berlin, Germany) was adminis-
ered as a hand-injected bolus of 0.1 mmol/kg
ollowed by a saline flush. LGE images were
cquired in each corresponding long- and short-axis
ine view using a 2-dimensional segmented turbo
ast low-angle shot inversion recovery sequence.
he inversion time was adjusted to optimize myo-
ardial nulling. The LGE images were repeatedA B B R E V I A T I O N S
A N D A C R O N YM S
ACE angiotensin-converti
enzyme
AICD automated implanta
cardioverter-defibrillator
CAD coronary artery disea
CI confidence interval
CMR cardiac magnetic
resonance
ECG electrocardiogram
EF ejection fraction
EP electrophysiology
HF heart failure
HR hazard ratio
IQR interquartile range
LGE late gadolinium
enhancement
LV left ventricle/ventricul
LVEF left ventricular
ejection fraction
NSVT nonsustained
ventricular tachycardia
RV right ventricle/ventricu
SCD sudden cardiac death
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337all areas of observed enhancement were cross-cut to
exclude artifact.
Image analysis. Ventricular function and volumes
were analyzed with dedicated software (CMRtools,
Cardiovascular Imaging Solutions, London, United
Kingdom) as previously described (27). All volume
and mass measurements were indexed to body
surface area (27). The entire short-axis LGE stack
of images was analyzed quantitatively for fibrosis
extent by 2 independent readers with customized
software (MRI-MASS, Medis, Leiden, the Neth-
erlands). The endocardial and epicardial borders
were traced for each short-axis slice. A region of
interest averaging 50 mm2 was defined within the
ormal remote myocardium in an area with uniform
yocardial suppression free of artifacts. A multipass
egion-growing algorithm was used to identify the
brotic boundaries on the basis of the “full width
alf maximum” technique; fibrosis was expressed as
resent or absent, and its extent was quantified as a
ercentage of total LV mass (20).
Follow-up data. Events data were collected in all
ases by communication with the patient via a
ailed questionnaire and by examination of the
rimary care physician’s records as well as examina-
ion of the referring hospital records. Mortality data
ere cross-checked with the Office of National
tatistics. Only new events after enrolment were
onsidered in the analysis. Patients were censored
fter reaching the composite endpoint, which was a
ombination of dysrhythmic cardiac death, cardiac
rrest, new episode of sustained VT or ventricular
brillation (VF), or appropriate AICD discharge, as
efined by a change in the configuration of the
tored ECG (28). Patients who underwent electro-
hysiology (EP) ablation for VT were censored at
he time of EP ablation, as this intervention skews
he natural course of an arrhythmic history.
Statistical analysis. All statistical analyses were per-
formed in SPSS version 18 (SPSS, Armonk, New
York). Results are presented as mean SD or n (%)
for continuous and categorical variables, respec-
tively. Comparisons between groups were made
with the independent Student t test of chi-square
cross-tabulations for continuous and categorical
data, respectively. Kaplan-Meier survival curves
were used to test the significance of each indepen-
dent variable as a predictor of the endpoint as a
comparator between groups. All demographic, clin-
ical, and scan variables that were significant univar-
iate predictors (with a p value 0.05) were subse-
quently entered in a multivariate model. Each Cox
proportional hazards model was constructed using pwith a forward conditional stepwise procedure. The
selected multivariate model was refitted without
using a stepwise procedure to avoid problems of
missing data in unselected variables. The assump-
tion of proportional hazards was checked using
graphical methods (29). The predictions from some
simple models were compared using the net reclas-
sification index (30).
R E S U L T S
Baseline characteristics. Between 1999 and 2009, a
otal of 373 patients were recruited. The baseline
haracteristics of the cohort are summarized in
able 1. They were followed up for a median of 2.6
ears (range 11 months to 11 years, interquartile
ange [IQR]: 1.1 to 3.6 years). Replacement fibrosis
as detected in 122 (33%) of patients on the LGE
tudy, 55 of whom received an AICD. The group
ith fibrosis was older by 8 years than the no-
brosis group and similar in ethnic origin. Fibrosis
as present in 38% of VT patients and 27% of
SVT patients (p  0.030). Coronary artery dis-
ase (CAD) (as diagnosed by coronary angiogra-
hy), heart failure (HF), and diabetes were signif-
cantly higher in the fibrosis group (p  0.01).
ibrosis was also more frequent in men versus
omen (42% vs. 17%, p  0.001). The fibrosis
roup was more likely to be receiving angiotensin-
onverting enzyme (ACE) inhibitors or beta-
lockers compared with the no-fibrosis group (p 
.001 for each medication). The resting ECG was
bnormal in 134 patients (T-wave inversion, ST/
-wave changes, voltage criteria of LV hypertro-
hy, left or right bundle branch block, atrial fibril-
ation, multiple ventricular ectopic beats, first-
egree atrioventricular block). After clinical
valuation (which included access to the CMR
eport), 116 patients with LVEF 35% were im-
lanted with an AICD.
CMR characteristics are presented in Table 2.
he mean LVEF of the entire study population was
0  13%. For the entire cohort (both NSVT and
T groups), patients with fibrosis had significantly
ncreased LV volumes and mass (both before and
fter they were normalized to body surface area, sex,
nd decile of age, p  0.001), reduced LVEF (p 
0.001), increased right ventricular (RV) volumes
(p  0.05), and reduced RVEF (p  0.004).
Fibrosis was located subepicardially (n  2), mid-
wall (n  69), subendocardially (n  18), transmu-
ally (n  23), or diffusely (n  10) in the total 122
atients who demonstrated late enhancement.
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338Patients with each of the 2 clinical presentations
were also analyzed separately (Table 2). In the VT
group, patients with fibrosis showed significant LV
and RV remodeling compared with those without
fibrosis. In the NSVT group, there was significant
LV remodeling in those with fibrosis, but there
were no differences in the RV volume parameters
between groups. When fibrosis was present, the
amount of fibrosis measured in the LV was com-
parable between the VT and NSVT subgroups.
Hard events. During follow-up, there were 6 non-
ardiac deaths, and 15 patients underwent EP
blation, all for VT. Fifty-three patients (35 in the
T and 18 in the NSVT group) reached the
omposite endpoint (15 [28%] cardiac death, 1
1.8%] cardiac arrest, 15 [28%] AICD discharge, 22
41%] sustained VT); and 9 patients met the
rimary outcome on 2 occasions (but were censored
t first event for analysis). Of the 53 reaching the
rimary outcome, 33 (62%) were in the fibrosis
roup. For the entire cohort, variables that were
ound to be significant univariate predictors of the
rimary outcome were a past medical history of
AD (log-rank chi-square test  5.8, p  0.016),
Table 1. Baseline Characteristics of the 373 Patients Enrolled
LGE Fibrosis ()
(n  251)
Age at recruitment, yrs 48 15
Male 139
Ethnicity
Caucasian 136
African-Caribbean/Asian 10
Unknown/other 105
Presentation
NSVT 124
VT 127
Medication
Aspirin 52
Beta-blocker 118
ACE inhibitor 56
Furosemide 8
Statin 51
Past medical history
Hypertension 47
Hypercholesterolemia 50
Diabetes 11
Heart failure 8
Coronary artery disease 5
Stroke 4
Values are mean  SD or n. Where a characteristic is clearly binary (medicatio
presented, and the p value is presented on the same row as the name of the ch
() and LGE ﬁbrosis positive () groups.
ACE  angiotensin-converting enzyme; LGE  late gadolinium enhancementn increased LV end-systolic volume (log-rank 0hi-square test  5.2, p  0.023), and presence of
GE fibrosis (log-rank chi-square test  22, p 
.001). Reduced LVEF was a significant predictor
f events in the univariate analysis, whether it was
epresented with a cutoff at LVEF 55% (log-rank
hi-square test  10, p  0.002), or a cutoff at
VEF 35% (log-rank chi-square test  6.1, p 
.014), or as 3 categories (35, 36 to 54, 55,
og-rank chi-square test 11.3, p 0.004) (Fig. 1A).
educed RVEF was similarly associated with the
vents, but added nothing extra when fitted in the
ame model with LVEF. The most inclusive list of
ariables offered to the forward stepwise selection
ncluded past medical history of myocardial infarc-
ion, of CAD and of HF, family history of SCD,
V end-systolic volume category, presence of LGE
brosis, and a representation of LVEF. In the
ultivariate model, the presence of fibrosis was the
nly independent predictor of the primary outcome
hazard ratio [HR]: 3.3, 95% confidence interval
CI]: 1.8 to 5.8, p  0.001). LVEF 55% had an
levated HR, but was not significant at the 5%
ignificance level for the primary outcome after
djusting for presence of fibrosis (HR: 1.4, 95% CI:
LGE Fibrosis ()
(n  122)
Total
(N  373) p Value
57 15 0.001
99 238 0.001
0.952
64 200
5 15
53 158
0.030
45 169
77 204
53 105 0.001
83 201 0.001
65 121 0.001
23 31 0.001
56 107 0.001
34 81 0.023
37 87 0.011
17 28 0.001
14 22 0.001
24 29 0.001
3 7 0.429
ed or not, disease present or not), only the counts for 1 of the 2 categories is
teristic. The p value represents comparisons between the LGE ﬁbrosis negative
T  nonsustained ventricular tachycardia; VT  ventricular tachycardia.n us
arac.7 to 2.5, p  0.31). No other representations of
s in
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339LVEF (cutoff at 35% or in 3 categories: LVEF
35, 36% to 54%, 55%) were significant after
adjusting for fibrosis. Given the significance of the
multivariate analysis of presence/absence of fibrosis
for the combined outcome, data were also repre-
sented with a cutoff at the median value of 10%
fibrosis: relative to having no fibrosis, having 10%
fibrosis, or 10% fibrosis showed a comparable
hazard of the composite endpoint (HR: 3.5, 95%
CI: 1.8 to 6.7; and HR: 3.7, 95% CI: 1.9 to 7.3,
respectively). Figure 1B shows the survival analysis
of the patients with fibrosis compared with those
without fibrosis, and Figure 1C shows the increase
in absolute risk of reaching the composite endpoint
for all patients with presence of fibrosis.
Subgroup analyses. In the sustained VT group, the
univariate variables that significantly influenced sur-
vival were a past medical history of CAD (chi-
square test  10.2, p  0.001) as well as presence
of LV fibrosis (chi-square test  12.1, p  0.001).
Reduced LVEF was a significant univariate predic-
tor whether divided into 3 categories, that is, LVEF
35%, 36% to 54%, 55%, (chi-square test 
13.2, p  0.001) (Fig. 2A) or using a cutoff at
LVEF 35% (chi-square test  12.9, p  0.001),
but not quite significant at the 5% level as a cutoff
at LVEF 55%.
The most inclusive list of variables offered to the
forward stepwise selection included past medical
Table 2. CMR Characteristics of the 373 Patients Enrolled
All Patients
LGE ()
(n  251)
LGE ()
(n  122) p Value
LVEDV, ml 154 43 213 86 0.001
LVEDVi, ml/m2 80 19 107 40 0.001
LVESV, ml 56 30 114 79 0.001
LVESVi, ml/m2 29 15 57 38 0.001
LVEF, % 65 10 51 16 0.001
LVM, g 140 43 178 79 0.001
LVMi, g/m2 73 19 89 36 0.001
RVEDV, ml 162 47 182 71 0.010
RVEDVi, ml/m2 80 28 75 47 0.337
RVESV, ml 69 31 90 57 0.001
RVESVi, ml/m2 34 17 37 31 0.248
RVEF, % 59 9 53 14 0.001
Fibrosis, absolute 0 (0) 16 (8–34) n/a
Fibrosis, % of LVM 0 (0) 10 (5–23) n/a
Values are mean  SD or median (IQR). p Values represent comparisons betwe
CMR  cardiac magnetic resonance; IQR  interquartile range; LVEDV  left
ejection fraction; LVESV  left ventricular end-systolic volume; LVESVi  left ve
right ventricular end-diastolic volume; RVEDVi  right ventricular end-diastolic
RVESVi  right ventricular end-systolic volume index; other abbreviations ahistory of CAD and of HF, family history of SCD,presence of LGE fibrosis, and a representation of
LVEF. Both LV fibrosis and a severely impaired
systolic function (LVEF 35%) appeared to be
significant predictors in the multivariate model
(HR: 3.0, 95% CI: 1.4 to 6.2, p  0.001, and HR:
2.5, 95% CI: 1.1 to 6.2, p  0.038, respectively).
There was no evidence of an interaction between
fibrosis and LVEF.
With a similar cutoff at the median value of 10%,
having 10% fibrosis, relative to having no fibrosis,
increased the hazard of the composite endpoint (HR:
2.9, 95% CI: 1.2 to 6.9), and having 10% fibrosis
similarly increased the risk (HR: 3.8, 95% CI: 1.7 to
8.2). Figure 2B shows the survival analysis of the VT
patients with fibrosis compared with those without
fibrosis. Figure 2C shows the increase in absolute risk
of reaching the composite endpoint for the VT pa-
tients with presence of fibrosis.
In the NSVT group, the univariate variables that
predicted the likelihood of reaching a primary
outcome were the LV mass index (log-rank chi-
square test  4.6, p  0.031), LVEF 55%
(log-rank chi-square test 7.2, p 0.007), and the
presence of LV fibrosis (log-rank chi-square test 
8.8, p  0.003). (LVEF represented as 3 categories
was also a significant predictor [log-rank chi-square
test  13.5, p  0.001], but LVEF cutoff at 35%
was not.) The most inclusive list of variables offered to
the forward stepwise selection included past medical
VT Patients (n  204) NSVT Patie
LGE ()
(n  127)
LGE ()
(n  77) p Value
LGE ()
(n  124)
LG
(n
153 43 218 86 0.001 154 43 20
80 19 107 40 0.001 81 20 10
58 29 117 80 0.001 54 31 11
30 15 58 39 0.001 28 15 5
64 10 51 16 0.001 66 9 5
142 44 170 78 0.006 137 42 19
74 18 83 35 0.033 71 19 9
164 50 191 73 0.008 161 43 16
81 29 79 48 0.771 78 28 6
72 35 97 61 0.002 66 26 7
35 18 40 33 0.226 32 15 3
58 10 52 14 0.008 60 8 5
0 (0) 16 (8–33) n/a 0 (0) 16
0 (0) 10 (6–23) n/a 0 (0) 10
he LGE negative () and LGE positive () groups.
ricular end-diastolic volume; LVEDVi  left ventricular end-diastolic volume inde
ular end-systolic volume index; LVM  left ventricular mass; LVMi  left ventricu
me index; RVEF  right ventricular ejection fraction; RVESV  right ventricular
Table 1.nts (n  169)
E ()
 45) p Value
5 86 0.001
5 40 0.001
0 78 0.001
7 39 0.001
1 18 0.001
2 81 0.001
8 36 0.001
6 67 0.634
9 46 0.184
7 49 0.190
2 28 0.982
6 13 0.072
(7–34) n/a
(4–20) n/a
en t
vent x; LVEF  left ventricular
ntric lar mass index; RVEDV 
volu end-systolic volume;history of CAD and of HF, family history of SCD,
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340ordered categories of LV mass index, presence of
LGE fibrosis, and a representation of LVEF. Patients
with NSVT and fibrosis were more likely to reach a
primary outcome (HR: 4.2, 95% CI: 1.7 to 10.1, p 
0.006) compared with those without fibrosis, and this
remained the only significant predictor in the multi-
variate model. Figure 3A shows the estimated survival
analysis of the NSVT patients with fibrosis compared
with those without fibrosis. Although there was an
elevated HR for the percentage of fibrosis, it was not
statistically significant (HR: 1.09, 95% CI: 0.91 to
1.29, p  0.331). Relative to having no fibrosis,
having 10% fibrosis significantly increased the haz-
ard of the composite endpoint (HR: 5.9, 95% CI: 2 to
17.3), but having 10% fibrosis did not (HR: 2.4,
5% CI: 0.7 to 8) (Fig. 3B).
The unadjusted and adjusted hazard ratios for all
ariables included in the Cox multivariate models
re presented in Table 3.
A net reclassification index (30) was used to
ompare risk prediction between LGE (as 3 cate-
ories: normal [no scarring], less than median
carring [10%] among those with scaring, median
r greater scarring among those with scaring) and
VEF (also as 3 ordered categories: normal
55%], high abnormal [36% to 54%], and low
bnormal [35%]). Higher proportions were clas-
ified as high risk using LGE 10% (34% of
atients with the outcome and 14% without) than
VEF 35% (15% and 6%, respectively). Overall,
here was marginally better risk prediction of the
omposite endpoint on the basis of LGE than on
VEF, but this did not reach statistical significance
p  0.10). Patients with VT showed the same
odest improvement in prediction with LGE than
VEF (p  0.13), and there was no difference for
atients with NSVT (p  0.59).
D I S C U S S I O N
The main findings of this study are:
1. In patients presenting with ventricular arrhyth-
mia (excluding those with arrhythmia of con-
genital or genetic etiology), the presence of
myocardial fibrosis is an important independent
predictor of the combined endpoint of cardiac
death, cardiac arrest, new episode of sustained
VT, VF, or appropriate AICD discharge.
2. In patients who presented with an episode of
sustained VT, both the presence of fibrosis on
CMR-LGE and a poor LVEF (35%) were
significant predictors of the combined endpoint. InEv
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Figure 1. Entire Cohort: Survival Analysis by EF and LGE,
and Proportional Hazards Relative to Extent of Fibrosis
(A) Kaplan-Meier estimated freedom from reaching the combined endpoint in
all 373 patients (sustained and nonsustained ventricular tachycardia [VT])
according to the left ventricular ejection fraction (EF) represented by 3 catego-
ries. (B) Entire cohort: survival analysis by late gadolinium enhancement (LGE).
Kaplan-Meier estimated freedom from reaching the combined endpoint in all
373 patients (sustained and nonsustained VT) according to presence or absence
of ﬁbrosis. (C) Entire cohort: proportional hazards relative to extent of ﬁbrosis.
Hazard ratios for reaching the composite endpoint for all 373 study patientsthis study, the assessment of fibrosis was not only an
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341independent predictor, but also a better predictor of
the composite endpoint than LVEF.
. In patients who presented with a previous
episode of NSVT, the presence of fibrosis on
CMR-LGE was the only independent predic-
tor of the combined endpoint.
These findings suggest that assessment of myo-
ardial fibrosis could be complementary to measure-
ent of LVEF for risk stratification and could
ring refinements to the current criteria for pre-
cription of AICD as well as identify other high-
isk groups that did not previously qualify.
A well-recognized mechanism for sudden cardiac
eath is the presence of fibrosis causing electrical
nstability in the LV myocardium through re-entrant
rrhythmias (31). In EP studies, a key aim is to
dentify areas of fibrosis as a focus for ablation. The
egative predictive value of a normal LGE-CMR has
lready been suggested in smaller studies, for example,
bsence of fibrosis in nonischemic cardiomyopathy
dentified a group at much lower risk (24). Conversely,
he presence of fibrosis in hypertrophic cardiomyopa-
hy (17,18,32), ischemic cardiomyopathy (22), or
ther nonischemic (21) cardiomyopathy identified
hose at higher risk. However, most of these studies
ollowed up patients who already qualified for an
ICD by the current criteria and therefore most had
everely depressed EF (35%).
Implications for secondary prevention. Our current
study was novel in enrolling all comers with VT and
NSVT, so that we can adequately compare the
individual impacts of LGE and LV remodeling
with respect to their predictive values. Indeed, the
mean EF of our study population was 60  13%.
This is markedly different from the landmark stud-
ies on the basis of which AICD is recommended for
secondary prevention by the current guidelines: in
the AVID trial (4), the mean EF of patients was
32%; in CASH (Cardiac Arrest Study Hamburg)
(2), the mean EF was 46%; and in CIDS (Canadian
Implantable Defibrillator Study) (3), the mean EF
was 33%. Our findings in the VT subgroup, which
identified an EF 35% and the presence of LV
fibrosis as the only 2 important predictors of hard
cardiovascular events after multivariate analysis,
is in agreement with the earlier studies: a poor EF
is a significant predictor of further ventricular
arrhythmia. However, an important finding in
this study is that the presence of LV fibrosis
appears to be a stronger predictor of events, even
in those with poor EF. The implication that in
those with mild-to-moderate LV impairment or nor-
mal LVEF, the presence of fibrosis is in fact theEv
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Figure 2. Sustained VT Group: Survival Analysis by EF and LGE,
and Proportional Hazards Relative to Extent of Fibrosis
(A) Kaplan-Meier estimated freedom from reaching the combined endpoint
in the 204 VT patients according to the left ventricular EF represented by 3
categories. (B) Sustained VT group: survival analysis by LGE. Kaplan-Meier
estimated freedom from reaching the combined endpoint in the 204
patients with sustained VT according to presence or absence of ﬁbrosis.
(C) Sustained VT group: proportional hazards relative to extent of ﬁbrosis.
Hazard ratios for reaching the composite endpoint for the 204 sustained VT
patients grouped into 3 categories: no ﬁbrosis, 10% ﬁbrosis, or 10%
ﬁbrosis. Abbreviations as in Figure 1.
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342only significant predictor of events, warrants further
exploration. Although current guidelines for AICD
implantation as secondary prevention list those with
sustained VT and structural heart disease as a Class
I, Level of Evidence: B indication, it is conceivable
that in vivo detection of fibrosis may be able to
identify those patients with structural heart disease
who could derive particular benefit from AICD
prescription. Our findings are in agreement with
the findings of Iles et al. (24), who showed a
LGE – 97 59 38 20 12 3 1 1 1 0
LGE + 35 20 11 4 2 1 0 0 0 0
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NSVT Group: Survival Analysis by LGE and Proportional
elative to Extent of Fibrosis
Meier estimated freedom from reaching the combined endpoint in
tients with nonsustained ventricular tachycardia (NSVT) according to
r absence of ﬁbrosis. (B) NSVT group: proportional hazards relative to
brosis. Hazard ratios for reaching the composite endpoint for the 169
nts grouped into 3 categories: no ﬁbrosis, 10% ﬁbrosis, or 10%
breviations as in Figure 1.significant difference between groups of patients twith structural heart disease who had fibrosis versus
those without fibrosis with respect to recurrence of
ventricular arrhythmia episodes.
Of the randomized controlled studies that com-
pared AICD implantation with antiarrhythmic
medication for secondary prevention, only AVID
demonstrated a statistically significant survival ben-
efit. This implies that better discrimination of those
patients who will use an AICD is desirable. If
confirmed by other studies, our findings have the
potential to refine the criteria for secondary preven-
tion, as already challenged by post hoc analyses of
landmark studies that identified that patients at
lower risk may not benefit from AICD implanta-
tion (7). Risk stratification inclusive of LV fibrosis
may contribute as a robust biomarker for arrhyth-
mia recurrence in these patients.
Implications for primary prevention. The primary
revention of ventricular arrhythmias remains a
ubject of intense debate. The group we studied has
n element of self-selection, as they already pre-
ented with an NSVT episode rather than being
rrhythmia naive (the same applied to randomized
ontrolled studies of primary prevention, for exam-
le, in those with nonischemic cardiomyopathy
nrolled in the DEFINITE [Defibrillators in Non-
schemic Cardiomyopathy Treatment Evaluation]
rial [33]). Although a depressed EF (35%) is the
ainstay for favoring AICD therapy in the current
uidelines, almost irrespective of etiology, our re-
ults were unable to confirm this because we had
ery few patients in the NSVT subgroup with
everely impaired EF (35%): 12 of 169. This is, of
ourse, expected, as in accordance with current
uidelines, those with poor EF would have been
rescribed an AICD by their attending cardiologist,
nd further investigation before device placement
ould often be deemed unnecessary. For the re-
aining majority of patients presenting with
SVT, our results showed that the presence of
brosis was the only predictor of the combined
utcome. This result is interesting because it opens
ew avenues of consideration for primary preven-
ion in groups that are not included by guidelines
nd are treated by individual consideration in cur-
ent medical practice.
Study limitations. Inevitably, there will be some
eferral bias dependent on referring physician prac-
ice. It is conceivable that those at greatest risk were
ot referred because an AICD was considered man-
atory on the basis of current guidelines. Also, risk in
his work is determined on the basis of a fixed ratherNumbers
at Risk
Ev
en
t-F
re
e 
Su
rv
iv
a
l
0.0
0.2
0.4
0.6
0.8
1.0
Pe
rc
e
n
ta
ge
 P
a
tie
nt
s
0
12
24
36
48
60
A
B
Figure 3.
Hazards R
(A) Kaplan-
the 169 pa
presence o
extent of ﬁ
NSVT patiehan a progressive review based on stratified assess-
1 an
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 3 , 2 0 1 3
M A R C H 2 0 1 3 : 3 3 5 – 4 4
Dawson et al.
CMR and Ventricular Arrhythmias
343ment. Our quantitative analysis of fibrosis assumed
calibration of signal intensity to a remote area of
myocardium considered normal—in practice it is also
conceivable that in disease states, diffuse fibrosis may
be present in the remote myocardium, and if so, this
would slightly alter the amount of calculated replace-
ment fibrosis by this technique.
C O N C L U S I O N S
In this study, we evaluated the prognostic signif-
icance of LV fibrosis in patients presenting with
a ventricular arrhythmia. Patients with detectable
myocardial fibrosis had a significantly higher risk
Table 3. Unadjusted and Adjusted HR for the Cox Proportional
Univariate Cox
(Unadjusted) HR CI
All patients
LVEF 35% 2.49 1.17–5.30
LVEF 55% 2.34 1.36–4.03
Presence of LGE 3.51 2.01–6.13
LGE 0% 1.00
LGE 0.1% to 9.9% 3.53 1.87–6.67
LGE 10% 3.74 1.91–7.34
LGE per 5% extra ﬁbrosis 1.12 1.03–1.22
VT
LVEF 35% 4.10 1.78–9.46
LVEF 55% 1.86 0.95–3.64
Presence of LGE 3.23 1.60–6.49
LGE 0% 1.00
LGE 0.1% to 9.9% 2.88 1.21–6.87
LGE 10% 3.79 1.75–8.20
LGE per 5% extra ﬁbrosis 1.13 1.02–1.25
NSVT
LVEF 35% 0.67 0.09–5.05
LVEF 55% 3.34 1.31–8.53
Presence of LGE 3.73 1.47–9.50
LGE 0% 1.00
LGE 0.1% to 9.9% 5.89 2.00–17.33
LGE 10% 2.44 0.74–8.12
LGE per 5% extra ﬁbrosis 1.09 0.92–1.29
*HR, 95% CI, and p value when LVEF 35 is ﬁtted in a model with presence o
CI  conﬁdence interval; HR  hazard ratio; other abbreviations as in TablesForce on Practice Guidelines (Writing R. Randomized comdeath, cardiac arrest, new episode of sustained
VT or VF, and appropriate AICD discharge. The
presence of fibrosis was the most significant
independent predictor in multivariate analyses
and may have merit as an important biomarker
for further risk stratification. These findings have
the potential to bring significant refinement in
prescribing AICD therapy for both primary and
secondary prevention.
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Value Chi-Square
Multivariate Cox
(Adjusted) HR CI p
0.018 6.0 1.44* 0.66–3.17
0.002 10.0 1.38† 0.74–2.53
0.001 22.2 3.26* 1.83–5.82 
rall 0.001 23.5
0.001
0.001
0.01 0.95
0.001 12.8 2.54* 1.05–6.18
0.069 3.4 1.21† 0.59–2.49
0.001 12.1 2.95* 1.39–6.25
erall 0.002 13.9
0.017
0.001
0.025 5.3
0.70 0.15 0.35* 0.05–2.70
0.012 7.2 1.83† 0.57–5.85
0.006 8.8 4.27* 1.66–10.99
erall 0.005 12.9
0.001
0.15
0.34 0.95
osis. †HR, 95% CI, and p value for LVEF 55% when ﬁtted in a model with prese
d 2.of reaching the combined outcome of cardiac abdn.ac.uk.R E F E R E N C E S
1. Epstein AE, DiMarco JP, Ellenbogen
KA, et al. ACC/AHA/HRS 2008
guidelines for device-based therapy of
cardiac rhythm abnormalities: a report
of the American College of Cardiology/
American Heart Association TaskCommittee to Revise the ACC/
AHA/NASPE 2002 Guideline Up-
date for Implantation of Cardiac
Pacemakers and Antiarrhythmia De-
vices). J Am Coll Cardiol 2008;51:
e1–62.
2. Kuck KH, Cappato R, Siebels J, Ruppel
parison of antiar-rhythmic drug therapy with implantable
defibrillators in patients resuscitatedMo
p Value Chi-Square
0.36 10.7
0.31 10.3
0.001
Ove
0.038 19.1
0.61 12.0
0.001
Ov
0.31 10.7
0.31 10.3
0.003
Ov
f ﬁbr nce of ﬁbrosis.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
g
n
t
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 3 , 2 0 1 3
M A R C H 2 0 1 3 : 3 3 5 – 4 4
Dawson et al.
CMR and Ventricular Arrhythmias
344from cardiac arrest: the Cardiac Arrest
Study Hamburg (CASH). Circulation
2000;102:748–54.
3. Connolly SJ, Gent M, Roberts RS, et
al. Canadian Implantable Defibrillator
Study (CIDS): a randomized trial of
the implantable cardioverter defibril-
lator against amiodarone. Circulation
2000;101:1297–302.
4. The Antiarrhythmics versus Implantable
Defibrillators (AVID) Investigators. A
comparison of antiarrhythmic-drug ther-
apy with implantable defibrillators in pa-
tients resuscitated from near-fatal ventric-
ular arrhythmias. N Engl J Med 1997;
337:1576–83.
5. Moss AJ, Greenberg H, Case RB, et al.
Long-term clinical course of patients after
termination of ventricular tachyarrhyth-
mia by an implanted defibrillator. Circu-
lation 2004;110:3760–5.
6. Domanski MJ, Sakseena S, Epstein
AE, et al. Relative effectiveness of the
implantable cardioverter-defibrillator
and antiarrhythmic drugs in patients
with varying degrees of left ventricular
dysfunction who have survived malig-
nant ventricular arrhythmias. J Am
Coll Cardiol 1999;34:1090–5.
7. Hallstrom AP, McAnulty JH, Wilkoff
BL, et al. Patients at lower risk of
arrhythmia recurrence: a subgroup in
whom implantable defibrillators may
not offer benefit. J Am Coll Cardiol
2001;37:1093–9.
8. Soejima K, Stevenson WG, Sapp JL,
Selwyn AP, Couper G, Epstein LM.
Endocardial and epicardial radiofre-
quency ablation of ventricular tachycar-
dia associated with dilated cardiomyop-
athy: the importance of low-voltage
scars. J Am Coll Cardiol 2004;43:
1834–42.
9. Bello D, Fieno DS, Kim RJ, et al.
Infarct morphology identifies patients
with substrate for sustained ventricular
tachycardia. J Am Coll Cardiol 2005;
45:1104–8.
0. Kim RJ, Fieno DS, Parrish TB, et al.
Relationship of MRI delayed contrast
enhancement to irreversible injury, in-
farct age, and contractile function. Cir-
culation 1999;100:1992–2002.
1. Kim RJ, Wu E, Rafael A, et al. The
use of contrast-enhanced magnetic
resonance imaging to identify revers-
ible myocardial dysfunction. N Engl
J Med 2000;343:1445–53.
2. Kwong RY, Chan AK, Brown KA, et
al. Impact of unrecognized myocardial
scar detected by cardiac magnetic reso-
nance imaging on event-free survival in
patients presenting with signs or symp-
toms of coronary artery disease. Circu-
lation 2006;113:2733–43.
3. Yokota H, Heidary S, Katikireddy CK,
et al. Quantitative characterization of
myocardial infarction by cardiovascularmagnetic resonance predicts future car-
diovascular events in patients with isch-
emic cardiomyopathy. J Cardiovasc
Magn Reson 2008;10:17.
4. Cheong BYC, Muthupillai R, Wilson
JM, et al. Prognostic significance of
delayed-enhancement magnetic reso-
nance imaging. Circulation 2009;120:
2069–76.
5. Assomull RG, Prasad SK, Lyne J, et
al. Cardiovascular magnetic reso-
nance, fibrosis, and prognosis in di-
lated cardiomyopathy. J Am Coll Car-
diol 2006;48:1977–85.
6. Kwong RY, Sattar H, Wu H, et al.
Incidence and prognostic implication
of unrecognized myocardial scar char-
acterized by cardiac magnetic reso-
nance in diabetic patients without
clinical evidence of myocardial infarc-
tion. Circulation 2008;118:1011–20.
7. Leonardi S, Raineri C, De Ferrari
GM, et al. Usefulness of cardiac mag-
netic resonance in assessing the risk of
ventricular arrhythmias and sudden
death in patients with hypertrophic
cardiomyopathy. Eur Heart J 2009;30:
2003–10.
8. Rubinshtein R, Glockner JF, Ommen
SR, et al. Characteristics and clinical
significance of late gadolinium en-
hancement by contrast-enhanced
magnetic resonance imaging in pa-
tients with hypertrophic cardiomyop-
athy. Circ Heart Fail 2010;3:51–8.
9. Adabag AS, Maron BJ, Appelbaum
E, et al. Occurrence and frequency of
arrhythmias in hypertrophic cardio-
myopathy in relation to delayed en-
hancement on cardiovascular mag-
netic resonance. J Am Coll Cardiol
2008;51:1369–74.
0. O’Hanlon R, Grasso A, Roughton M,
et al. Prognostic significance of myo-
cardial fibrosis in hypertrophic cardio-
myopathy. J Am Coll Cardiol 2010;
56:867–74.
1. Wu KC, Weiss RG, Thiemann DR,
et al. Late gadolinium enhancement
by cardiovascular magnetic resonance
heralds an adverse prognosis in nonisch-
emic cardiomyopathy. J Am Coll Car-
diol 2008;51:2414–21.
2. Roes SD, Borleffs CJW, van der Geest
RJ, et al. Infarct tissue heterogeneity as-
sessed with contrast-enhanced MRI pre-
dicts spontaneous ventricular arrhythmia
in patients with ischemic cardiomyopathy
and implantable cardioverter-defibrillator.
Circ Cardiovasc Imaging 2009;2:183–90.
3. Heidary S, Patel H, Chung J, et al.
Quantitative tissue characterization of
infarct core and border zone in pa-
tients with ischemic cardiomyopathy
by magnetic resonance is associated
with future cardiovascular events.
J Am Coll Cardiol 2010;55:2762–8. t4. Iles L, Pfluger H, Lefkovits L, et al.
Myocardial fibrosis predicts appropriate
device therapy in patients with implant-
able cardioverter-defibrillators for primary
prevention of sudden cardiac death. J Am
Coll Cardiol 2011;57:821–8.
5. Nazarian S, Bluemke DA, Lardo AC,
et al. Magnetic resonance assessment of
the substrate for inducible ventricular
tachycardia in nonischemic cardiomy-
opathy. Circulation 2005;112:2821–5.
6. Bogun FM, Desjardins B, Good E, et
al. Delayed-enhanced magnetic reso-
nance imaging in nonischemic cardio-
myopathy: utility for identifying the
ventricular arrhythmia substrate. J Am
Coll Cardiol 2009;53:1138–45.
7. Maceira AM, Prasad SK, Khan M,
Pennell DJ. Normalized left ventricu-
lar systolic and diastolic function by
steady state free precession cardiovas-
cular magnetic resonance. J Cardio-
vasc Magn Reson 2006;8:417–26.
8. Wood MA, Stambler BS, Damiano
RJ, Greenway P, Ellenbogen KA, for
the Guardian ATP 4210 Multicenter
Investigators Group. Lessons learned
from data logging in a multicenter
clinical trial using a late-generation
implantable cardioverter-defibrillator.
J Am Coll Cardiol 1994;24:1692–9.
9. Mahesh K, Parmar B, Machin D.
Cox’s proportional hazards model. In:
Machin D, Cheung YB, Parmar M,
editors. Survival Analysis: A Practical
Approach. Chichester, United King-
dom: Wiley, 1995:138–40.
0. Pencina MJ, D’Agostino RB Sr.,
D’Agostino RB Jr., Vasan RS. Evalu-
ating the added predictive ability of a
new marker: from area under the
ROC curve to reclassification and be-
yond. Stat Med 2008;27:157–72.
1. Ashikaga H, Sasano T, Dong J, et al.
Magnetic resonance-based anatomical
analysis of scar-related ventricular tachy-
cardia. Circ Res 2007;101:939–47.
2. Kwon DH, Smedira NG, Rodriguez
ER, et al. Cardiac magnetic resonance
detection of myocardial scarring in
hypertrophic cardiomyopathy: corre-
lation with histopathology and preva-
lence of ventricular tachycardia. J Am
Coll Cardiol 2009;54:242–9.
3. Kadish A, Dyer A, Daubert JP, et al.
Prophylactic defibrillator implantation
in patients with nonischemic dilated
cardiomyopathy. N Engl J Med
2004;350:2151–8.
Key Words: cardiac magnetic
resonance y fibrosis y late
adolinium enhancement y
onsustained ventricular
achycardia y ventricular
achycardia.
